Company Description
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products.
Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor.
Portage Biotech Inc. is based in Tortola, British Virgin Islands.
| Country | British Virgin Islands |
| Founded | 1973 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Alexander Pickett |
Contact Details
Address: Clarence Thomas Building, P.O. Box 4649 Tortola, VG1110 British Virgin Islands | |
| Phone | 302 219 5556 |
| Website | portagebiotech.com |
Stock Details
| Ticker Symbol | PRTG |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001095435 |
| CUSIP Number | G7185A128 |
| ISIN Number | VGG7185A1286 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter Molloy | Chief Executive Officer of Cyncado Therapeutics Inc. |
| Alexander Pickett | Chief Executive Officer and Director |
| Dr. Robert A. Kramer Ph.D. | Chief Scientific Officer |
| Adam Melero | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 1, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 28, 2025 | 424B3 | Prospectus |
| Jul 25, 2025 | 424B3 | Prospectus |
| Jul 25, 2025 | 6-K | Report of foreign issuer |
| Jul 25, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Jun 27, 2025 | 424B3 | Prospectus |
| Jun 27, 2025 | 6-K | Report of foreign issuer |
| Jun 27, 2025 | 424B5 | Filing |
| Jun 25, 2025 | 424B3 | Prospectus |
| Jun 25, 2025 | 6-K | Report of foreign issuer |